All manuscripts
Publications CAR T Cells T-Cells G-Rex®100M G-Rex®6 Well Plate

Large-scale manufacturing of base-edited chimeric antigen receptor T cells

Published Journal Molecular Therapy Methods & Clinical Development

Share
15 pages Large-scale manufacturing of base-edited chimeric antigen receptor T cells — Molecular Therapy Methods & Clinical Development, 2023

Overview

This study develops a protocol for manufacturing base-edited CAR-T cells using circular RNA (circRNA) to reduce costs and improve stability compared to linear mRNA. Large-scale production of PD-1 deficient CAR-T cells was achieved using 100M and six-well G-Rex® vessels, demonstrating scalability.

What this paper found

Circular RNA encoding the cytosine base editor BE4max disrupted PD-1 in primary human T cells more efficiently than linear mRNA, and supported manufacture of a clinical-scale dose of base-edited anti-CD19 CAR T cells. CircRNA was produced by Anabaena permuted intron-exon self-splicing with a mean circularization efficiency of 68.7%, and gave higher BE4max protein levels despite similar RNA decay, cutting the RNA requirement about 8-fold. In a semi-closed process, CD4+/CD8+ cells selected on the CliniMACS Prodigy were activated, nucleofected on day 2, transduced with an anti-CD19 CAR on day 3, and expanded 2- to 3-fold to about 1 × 10^8 cells by day 9. On-target C-to-T conversion reached 86% with 0.25 µg and 100% with 1.00 µg circRNA per 1 × 10^6 cells.

Note: The authors state that off-target events were not assessed in this study because the PD-1 guide RNA sequence had been validated previously.

In summary, we demonstrate the application of circRNA for base editing in primary T cells and prove that it is superior to linear mRNA. — Rosie Woodruff, Farhaan Parekh, Katarina Lamb, Leila Mekkaoui, Christopher Allen, Katerina Smetanova, Jasmine Huang, Alex Williams, Gerardo Santiago Toledo, Koki Lilova, Claire Roddie, James Sillibourne, Martin Pule, Molecular Therapy Methods & Clinical Development

Study details

Authors
Rosie Woodruff, Farhaan Parekh, Katarina Lamb, Leila Mekkaoui, Christopher Allen, Katerina Smetanova, Jasmine Huang, Alex Williams, Gerardo Santiago Toledo, Koki Lilova, Claire Roddie, James Sillibourne, Martin Pule
Institution
Autolus Therapeutics, London, UK · Imperial College London, London, UK · Department of Haematology, Cancer Institute, London, UK
Journal
Molecular Therapy Methods & Clinical Development
Year
2023
PMID / PMC
PMID: 37886606 · PMC
G-Rex® model(s)
G-Rex®100M, G-Rex®6 Well Plate
Cell type(s)
CAR T Cells, T-Cells
Application area
Hematologic malignancy
Study phase
Preclinical

How G-Rex® was used

In the large-scale process, CD4+/CD8+ T cells selected from leukapheresate on the CliniMACS Prodigy were activated with GMP-grade TransAct and cultured in a 100M G-Rex® (RU81100). After nucleofection with BE4max circRNA and the PD-1 or non-targeting sgRNA on day 2, the base-edited T cells were cultured in a six-well G-Rex® (80240M) and left to recover overnight before lentiviral transduction with the anti-CD19 CAR on day 3. Starting from about 5 × 10^6 nucleofected cells, the cultures expanded roughly 2- to 3-fold to reach about 1 × 10^8 CAR T cells by day 9, when they were cryopreserved.

Note: Transduction itself was performed outside the gas-permeable vessels, in RetroNectin-coated 100-mL differentiation bags seeded at 1 × 10^6 cells/mL with lentiviral supernatant.

Explore related

Full citation

Woodruff R, Parekh F, Lamb K, et al. Large-scale manufacturing of base-edited chimeric antigen receptor T cells. Mol Ther Methods Clin Dev. 2023;31:101123.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →